



1637
Image

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on the date shown below:
October 30, 2003.

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT
Examining Group 1637
Patent Application
Docket No. G-036US03DIV
Serial No. 09/903,190

Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Suryaprabha Chundru
Art Unit : 1637
Applicant(s) : Jean-Baptiste Dumas Milne Edwards, *et al.*
Serial No. : 09/903,190
Filed : July 11, 2001
Conf. No. : 9722
For : Complementary DNAs

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

This information is being submitted prior to the mailing of a first office action on the merits.

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO/SB/08 with initials or other appropriate marks. If any additional fee is required, or to credit any overpayment, please use Deposit Account No. 19-0065.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik
A Professional Association
2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

FCE/ssa

Attachments: Form PTO/SB/08A & B
Copies of references cited



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/903,190
Filing Date	July 11, 2001
First Named Inventor	J.-B. Dumas Milne Edwards
Group Art Unit	1637
Examiner Name	Suryaprabha Chundru
Attorney Docket Number	G-036US03DIV

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	SOBANOV, Y. <i>et al.</i> , "A novel cluster of lectin-like receptor genes expressed in monocytic, dendritic and endothelial cells maps close to the NK receptor genes in the human NK gene complex", <i>Eur. J. Immunol.</i> (2001), 31:3493-3503.	
	R2	COLONNA, M. <i>et al.</i> , "Molecular characterization of two novel C-type lectin-like receptors, one of which is selectively expressed in human dendritic cells", <i>Eur. J. Immunol.</i> , (2000), 30:697-704.	
	R3	SAWAMURA, T. <i>et al.</i> , "An endothelial receptor for oxidized low-density lipoprotein", <i>Nature</i> (1997), 386(6):73-77.	
	R4	PARTHASARATHY, S. <i>et al.</i> , "Oxidized low-density lipoprotein, a two-faced Janus in coronary artery disease?", <i>Biochem. Pharmacol.</i> (1998), 56:279-284.	
	R5	Database PubMed, Accession No. NP_057593; Sobanov, Y. <i>et al.</i> & Colonna, M., <i>et al.</i> , C-type lectin-like receptor-2 [Homo sapiens], Medline 21610618 & 20135876; PubMed 11745369 & 10671229	
	R6	Database EMBL, Accession No. Q9P126; Colonna, M., <i>et al.</i> C-type lectin-like receptor-2, Created 10/01/2000, Medline 20135876, PubMed 10671229.	
	R7	Database PubMed, Accession No. AAF36777; Colonna, M. <i>et al.</i> , C-type lectin-like receptor-2 [Homo sapiens], Medline 20135876, PubMed 10671229	
	R8	Database PubMed, Accession No. NP_064369; Colonna, M. <i>et al.</i> , C-type lectin-like receptor 2 [Mus musculus], Medline 20135876, PubMed 10671229.	
	R9	Database PubMed, Accession No. AAF36831; Colonna, M. <i>et al.</i> , C-type lectin-like receptor 2 [Mus musculus], Medline 20135876, PubMed 10671229.	
	R10	Database PubMed, Accession No. AB010710; Sawamura, T. <i>et al.</i> , Homosapiens mRNA for lectin-like oxidized LDL receptor, complete cds., Medline 97205278, PubMed 9052782.	
	R11		
	R12		
	R13		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

J:\GEN\036.US03.DIV\PTO-Misc\SIDS-1449_3.doc\SIDS/ssa